Asthma is a chronic inflammatory disease of the airways in the lungs of children and adults.
The patient usually complains of shortness of breath, chest tightness and coughing with wheezing.
A diagnosis of asthma in young children is more likely if they have
symptom patterns, presence of risk factors for development of asthma and
therapeutic response to controller treatment.
Goals of treatment are effective symptom control with minimal or no
exacerbations, minimal or no nocturnal and daytime symptoms, no
limitations on activities, minimal or no need for reliever treatment,
and minimal adverse effects of medication.
Serum levels of biopterin correlate with the state of the asthma control at follow-up visit in children with stable disease, as shown in a recent study. Therefore, monitoring biopterin levels represent an attractive strategy to assess disease control status and to adjust treatment intensity more precisely.
In children with moderate or severe asthma exacerbations, the presence of respiratory pathogens such as respiratory syncytial virus, influenza and parainfluenza appears to increase the risk of treatment failure, a study reports.
Dupilumab, the fully human anti-interleukin-4 receptor α monoclonal antibody indicated for the treatment of atopic dermatitis, appeared to improve lung function, reduce exacerbations, and decrease oral corticosteroid use in individuals with moderate-to-severe asthma, according to two phase III trials presented at ATS 2018.
Frequent use of antibiotics during pregnancy is associated with an increased risk of childhood asthma, with the risk varies by timing and number of antibiotic courses used during pregnancy, according to a study presented at ATS 2018.
Adding tiotropium to inhaled corticosteroids (ICS) appeared safe and well tolerated in preschool children with persistent asthmatic symptoms, reveals an exploratory, regulatory trial—suggesting that tiotropium may be a complementary strategy for managing this young population for whom treatment options are scarce.
A temporary increased dose of inhaled glucocorticoids did not reduce the rate of exacerbations in children with mild-to-moderate asthma, according to a study presented at the 2018 AAAAI/WAO congress held in Orlando, Florida, US.
Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.